News

As anyone affected by a rare disease knows, treating the illness while trying to go about everyday life is an expensive undertaking.  But exactly how expensive — in terms of direct and indirect costs across rare disease populations — might still come as a surprise: almost…

The ability of Ofev (nintedanib) to improve lung function in people with progressive fibrosing interstitial lung diseases (ILDs) is not influenced by their use of immunomodulatory therapies, a study indicates. The study, “Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases,” was published in the journal…

Changes for the better in diagnosing idiopathic pulmonary fibrosis (IPF) and managing patients in the U.K. are evident in recent years, a real-world study based on registry data indicates. “Patient registries offer a unique opportunity to collect longitudinal data on uncommon diseases, such as IPF,” the researchers…

Lassen Therapeutics and researchers at Cedars Sinai Medical Center in California will together investigate the role of the immune signaling protein interleukin-11 (IL-11) in idiopathic pulmonary fibrosis (IPF), and its potential as a…

Exposure to fine particulate air pollutants, such as PM2.5 and nitric oxide (NO), raises the risk for acute flare-ups of idiopathic pulmonary fibrosis (IPF) within a time window of one to two months, according to data from a recent study. The study, “Exposure to PM2.5 is…

VeriSIM Life has launched a pharmaceutical subsidiary called PulmoSIM Therapeutics (PulmoSIM) to search for new treatments for rare lung diseases. Using artificial intelligence, PulmoSIM’s goal is to assess which therapies previously approved by the U.S. Food and Drug Administration for certain conditions can be effective for the treatment of…

A modified protein called citrullinated vimentin (cit-vim), released by immune cells in response to harmful pollutants, may contribute to lung scarring in people with idiopathic pulmonary fibrosis (IPF), a study reports. These findings suggest that cadmium and carbon black, which can be found in cigarette smoke as well as…

The University of Pittsburgh School of Medicine and Yale University School of Medicine were selected to join the Three Lakes Consortium for Pulmonary Fibrosis to help advance the development of new treatments for pulmonary fibrosis (PF). As part of the consortium, both universities will be collaborating with…

The key topics of discussion during a new webinar for people with pulmonary fibrosis (PF) focused on strategies — ranging from getting appropriate vaccines and managing individual symptoms to taking advantage of palliative and support care — for improving patient quality of life. The talk was given by Marlies…

CohBar has chosen CB5138-3 as its lead treatment candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, based on its promising safety, efficacy, and drug-like properties in preclinical studies. The company is planning to further test this peptide — a small protein fragment — in early studies…